Axsome Therapeutics (AXSM) Projects $638.5M Revenue for 2025, 66% Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Source: NASDAQ.COM
- Quarterly Revenue Expectation: Axsome Therapeutics anticipates approximately $196 million in product revenue for Q4 2025, reflecting a robust 65% year-over-year growth compared to Q4 2024, indicating strong market performance and sustained product demand.
- Annual Revenue Outlook: The company projects total product revenue of about $638.5 million for the full year 2025, representing a 66% annual growth, suggesting Axsome's continued expansion in market share and profitability in the coming year.
- AUVELITY Sales Forecast: Axsome expects AUVELITY net product sales to reach approximately $155.1 million in Q4 2025 and $507.1 million for the full year, showcasing strong market acceptance and sales potential for this product.
- Market Growth Potential: The revenue growth expectations not only highlight the competitive edge of Axsome's products but also indicate the company's ongoing innovation and strategic positioning in the biopharmaceutical sector, likely attracting increased investor interest.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like AXSM with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on AXSM
Wall Street analysts forecast AXSM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AXSM is 196.82 USD with a low forecast of 148.00 USD and a high forecast of 248.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 185.170
Low
148.00
Averages
196.82
High
248.00
Current: 185.170
Low
148.00
Averages
196.82
High
248.00
About AXSM
Axsome Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people living with central nervous system (CNS) conditions. The Company's commercial products include Auvelity, Sunosi and Symbravo. It is also advancing a diversified, late-stage pipeline of product candidates for serious neurological and psychiatric conditions, which include AXS-05, AXS-12, AXS-14 and AXS-17. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. Symbravo (meloxicam and rizatriptan, 20 mg/10mg tablets) is an oral, single-dose medicine approved for the acute treatment of migraine with or without aura in adults.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CommVault and Axsome Options Trading Activity Surges
- CommVault Options Volume: Today, CommVault Systems Inc's options volume reached 5,370 contracts, representing approximately 537,000 shares, which constitutes about 92.7% of its average daily trading volume over the past month, indicating heightened market interest in its future performance.
- High Demand for Call Options: Notably, the $90 strike call option expiring on February 20, 2026, saw 1,031 contracts traded today, representing around 103,100 shares, suggesting an increased investor expectation for CommVault's stock price appreciation.
- Axsome Options Volume: Axsome Therapeutics Inc recorded an options trading volume of 7,271 contracts, equating to approximately 727,100 shares, or about 81.4% of its average daily trading volume over the past month, reflecting strong market confidence in its growth potential.
- Strong Performance of Call Options: Particularly, the $280 strike call option expiring on April 17, 2026, traded 5,527 contracts today, representing approximately 552,700 shares, indicating optimistic investor sentiment regarding Axsome's future performance.
Continue Reading
Piper Sandler Raises Axsome Therapeutics (AXSM) Price Target to $223, Optimistic on Alzheimer’s Drug Potential
- Price Target Increase: Piper Sandler raised Axsome Therapeutics' price target from $148 to $223 while maintaining an Overweight rating, reflecting strong confidence in Auvelity's potential for FDA label expansion in Alzheimer's agitation.
- Financial Model Update: Baird increased Axsome's price target from $157 to $209 based on an update to its financial model following preliminary Q4 2025 results that slightly exceeded expectations, further boosting market confidence.
- Sales Beat Expectations: Wells Fargo raised Axsome's price target from $157 to $193, noting that Q4 2025 sales for Auvelity and Sunosi surpassed consensus estimates, which is expected to drive continued positive momentum for the stock.
- Increased Success Probability: Wells Fargo raised the probability of success for Alzheimer's Disease Agitation from 75% to 90% following the FDA's decision to grant priority review, indicating optimistic expectations for the drug's future market performance.
Continue Reading